Literature DB >> 30657585

Downregulation of plasma miR-124 expression is a predictive biomarker for prognosis of glioma.

L-Q Wang1, W Sun, Y Wang, D Li, A-M Hu.   

Abstract

OBJECTIVE: MicroRNAs (miRNAs) have been widely identified as potential biomarkers for predicting prognosis of glioma. The objective of the study was to examine the clinical role of plasma miR-124 expression in glioma. PATIENTS AND METHODS: MiR-124 expression in plasma samples from 64 cases glioma patients and 40 normal healthy controls was examined by quantitative reverse transcription PCR (qRT-PCR). The correlation of miR-124 expression with clinicopathological feathers or prognosis of glioma patients was assessed. Univariate and multivariate Cox analysis were used to analyze the risk factors of prognosis. The receiver operating characteristic (ROC) curve was established, and the area under the ROC curve (AUC) was calculated to evaluate the difference of miR-124 expression in glioma patients.
RESULTS: We showed that miR-124 expression was significantly downregulated in plasma samples of glioma patients compared with normal healthy controls (p<0.05). Plasma miR-124 expression significantly associated with Karnofsky Performance Status (KPS) score (p<0.05) and WHO grade (p<0.05) in glioma plasma. Patients with low miR-124 expression had worse disease free survival (DFS) and overall survival (OS) time than patients with high miR-124 expression. Univariate and multivariate analysis implied that low miR-124 expression was an independent maker of disease free survival (DFS) and overall survival (OS) in glioma.
CONCLUSIONS: Our findings implied that plasma miR-124 expression may serve as an independent predictor of poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30657585     DOI: 10.26355/eurrev_201901_16773

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

1.  Gain of circBRAF Represses Glioma Progression by Regulating miR-1290/FBXW7 Axis.

Authors:  Jinchao Zhang; Zhi Chen; Xinjun Liu; Chonglin Yang; Donggen Xie
Journal:  Neurochem Res       Date:  2021-03-02       Impact factor: 3.996

2.  Determining KLF14 tertiary structure and diagnostic significance in brain cancer progression.

Authors:  Kainat Zahra; Maria Shabbir; Yasmin Badshah; Janeen H Trembley; Zunaira Badar; Khushbukhat Khan; Tayyaba Afsar; Ali Almajwal; Nawaf W Alruwaili; Suhail Razak
Journal:  Sci Rep       Date:  2022-05-16       Impact factor: 4.996

Review 3.  MicroRNA-124: An emerging therapeutic target in cancer.

Authors:  Xinqi Jia; Xu Wang; Xiaorong Guo; Jingjing Ji; Ge Lou; Junjie Zhao; Wenjia Zhou; Mian Guo; Maomao Zhang; Chao Li; Sheng Tai; Shan Yu
Journal:  Cancer Med       Date:  2019-08-06       Impact factor: 4.452

4.  MicroRNA-769-3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/β-catenin signaling pathway.

Authors:  Kai Wang; Shasha Yang; Yishen Gao; Caihong Zhang; Qiangbo Sui
Journal:  Oncol Lett       Date:  2019-11-21       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.